BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22217342)

  • 1. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.
    Doublier S; Belisario DC; Polimeni M; Annaratone L; Riganti C; Allia E; Ghigo D; Bosia A; Sapino A
    BMC Cancer; 2012 Jan; 12():4. PubMed ID: 22217342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.
    Riganti C; Doublier S; Viarisio D; Miraglia E; Pescarmona G; Ghigo D; Bosia A
    Br J Pharmacol; 2009 Apr; 156(7):1054-66. PubMed ID: 19298255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
    Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
    Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity.
    Fang Y; Sullivan R; Graham CH
    Exp Cell Res; 2007 Mar; 313(5):867-77. PubMed ID: 17289019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells.
    Li Z; Zhu Q; Hu L; Chen H; Wu Z; Li D
    Cancer Sci; 2015 Aug; 106(8):1041-9. PubMed ID: 26079208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma.
    Shi D; Shi G; Huang G; Zhang J; Lartigau E
    J Exp Clin Cancer Res; 2009 Jun; 28(1):72. PubMed ID: 19490637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human recombinant FSH induces chemoresistance in human breast cancer cells via HIF-1α activation†.
    Bergandi L; Canosa S; Pittatore G; Silvagno F; Doublier S; Gennarelli G; Benedetto C; Revelli A
    Biol Reprod; 2019 Jun; 100(6):1521-1535. PubMed ID: 30939201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.
    Seebacher NA; Richardson DR; Jansson PJ
    Br J Pharmacol; 2015 May; 172(10):2557-72. PubMed ID: 25586174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
    Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
    Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.
    Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Peters AM
    Acta Oncol; 2004; 43(5):443-52. PubMed ID: 15360048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular Doppler Spectroscopy detects altered drug response in SKOV3 tumor spheroids with silenced or inhibited P-glycoprotein.
    Narayanan G; Merrill D; An R; Nolte DD; Turek JJ
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1154-1159. PubMed ID: 31103263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
    Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
    Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance.
    Yang JY; Ha SA; Yang YS; Kim JW
    BMC Cancer; 2010 Jul; 10():388. PubMed ID: 20649952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.
    Riganti C; Doublier S; Aldieri E; Orecchia S; Betta PG; Gazzano E; Ghigo D; Bosia A
    Eur Respir J; 2008 Aug; 32(2):443-51. PubMed ID: 18385176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
    Shabbits JA; Mayer LD
    Mol Cancer Ther; 2002 Jan; 1(3):205-13. PubMed ID: 12467215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
    Walker J; Martin C; Callaghan R
    Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
    Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
    Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.
    Pinzón-Daza ML; Cuellar-Saenz Y; Nualart F; Ondo-Mendez A; Del Riesgo L; Castillo-Rivera F; Garzón R
    J Cell Biochem; 2017 Jul; 118(7):1868-1878. PubMed ID: 28106284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
    Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
    Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
    Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
    Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.